Difference between revisions of "Adrenocortical carcinoma - null regimens"
Jump to navigation
Jump to search
m (→Placebo) |
m (→Regimen) |
||
| Line 19: | Line 19: | ||
|[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70081-1/fulltext Fassnacht et al. 2015 (GALACCTIC)] | |[https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70081-1/fulltext Fassnacht et al. 2015 (GALACCTIC)] | ||
|2009-2011 | |2009-2011 | ||
| − | |style="background-color:#1a9851"|Phase | + | |style="background-color:#1a9851"|Phase 3 (C) |
|[[#Linsitinib_monotherapy_99|Linsitinib]] | |[[#Linsitinib_monotherapy_99|Linsitinib]] | ||
|style="background-color:#ffffbf"|Did not meet primary endpoint of OS<br>Median OS: 356 vs 323 days | |style="background-color:#ffffbf"|Did not meet primary endpoint of OS<br>Median OS: 356 vs 323 days | ||
| Line 25: | Line 25: | ||
|} | |} | ||
''No active antineoplastic treatment.'' | ''No active antineoplastic treatment.'' | ||
| + | |||
===References=== | ===References=== | ||
# '''GALACCTIC:''' Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70081-1/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/25795408 PubMed] NCT00924989 | # '''GALACCTIC:''' Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(15)70081-1/fulltext link to original article] [https://pubmed.ncbi.nlm.nih.gov/25795408 PubMed] NCT00924989 | ||
Revision as of 14:18, 7 February 2022
The purpose of this page is to provide references to "null therapy" such as placebo and observation. While not clinically relevant, these references provide further insight into the historical development of the treatment landscape. See the main adrenocortical carcinoma page for current regimens.
Recurrent, locally advanced, or metastatic disease
Placebo
| back to top |
Regimen
| Study | Years of enrollment | Evidence | Comparator | Comparative Efficacy |
|---|---|---|---|---|
| Fassnacht et al. 2015 (GALACCTIC) | 2009-2011 | Phase 3 (C) | Linsitinib | Did not meet primary endpoint of OS Median OS: 356 vs 323 days |
No active antineoplastic treatment.
References
- GALACCTIC: Fassnacht M, Berruti A, Baudin E, Demeure MJ, Gilbert J, Haak H, Kroiss M, Quinn DI, Hesseltine E, Ronchi CL, Terzolo M, Choueiri TK, Poondru S, Fleege T, Rorig R, Chen J, Stephens AW, Worden F, Hammer GD. Linsitinib (OSI-906) versus placebo for patients with locally advanced or metastatic adrenocortical carcinoma: a double-blind, randomised, phase 3 study. Lancet Oncol. 2015 Apr;16(4):426-35. Epub 2015 Mar 18. link to original article PubMed NCT00924989